This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Patient access to Advanced Therapies in Europe 2009-2021: from early access failures to current challenges
Published on: Aug 3rd, 2021
The recent announcement of BlueBirdBio to wind down its European commercialisation efforts due to access and pricing challenges for its gene therapy products has put a new spotlight on the market access and payer environment for advanced therapies in Europe.
In this webinar VCLS market access experts analyse the commercial failures of advanced therapies, discuss key HTA challenges for these products in European markets and how to plan ahead to overcome them.
SAMPLE OF THE WEBINAR
Patient access to Advanced Therapies in Europe 2009 2021 from early access failures to current chal
Access the full webinar replay now
Fill in the form to download the content